Serum glutamate is associated with the motor subtype of Parkinson’s disease
Objective: We aimed to study the concentration of glutamate in the serum of patients with Parkinson's disease (PD) and its connection with clinical variants of…Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson’s Disease
Objective: To evaluate whether safinamide inhibits in vivo glutamate (Glu) release in a rodent model of Parkinson’s disease (PD), i.e. the 6-hydroxydopamine (6-OHDA) hemilesioned rat.…A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID
Objective: Objective was to assess the therapeutic potential of our novel mGlu4 positive allosteric modulator (PAM), foliglurax, as an anti-parkinsonian treatment in gold-standard primate models.…Use of safinamide: A clinical practice review of 2 year experience
Objective: Review the clinical use, efectivity and side efects in a population based cohort. Background: Safinamide is an oral, once a day adjunctive therapy for…The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…Long-term efficacy of safinamide on mood in Parkinsonian patients with fluctuations
Objective: The present post-hoc analysis of the results of two pivotal trials (016 and 018) investigated the effects of safinamide 100 mg/day on mood in…SLC6A17 mutations are not a common cause of intellectual disability and movement disorders in a large cohort of consanguineous Iranian families
Objective: To determine the prevalence of SLC6A17 mutations in a cohort of Iranian patients with intellectual disability and movement disorders. Background: Mutations in the SLC6A17…Density of metabotropic glutamate receptors subtype 1 in de novo patients with Parkinson’s disease using 11C-ITMM PET
Objective: To investigate the mapping of metabotropic glutamate receptor subtype 1 (mGluR1) in elderly normal and de novo patients with Parkinson's disease (PD) using N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-4-11C…Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia
Objective: To evaluate the role of the atypical vesicular glutamate transporter 3 (VGLUT3) and the vesicular acetylcholine transporter (VAChT) in L-DOPA-induced dyskinesia. Background: Parkinson's disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.